Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma

Completed · Phase 2

Conditions studied: Metastatic Osteosarcoma

In brief

Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and kill them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. Phase II trial to study the effectiveness of chemotherapy with or without trastuzumab in treating patients who have metastatic osteosarcoma

Key facts

Study ID
NCT00023998
Run by
National Cancer Institute (NCI)
People needed
80
Starts
2001-07-01
Expected to finish
2007-05-01
Last updated by the study team
2013-02-04

Who can join

Age: any, up to 30. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.